The 86th Scientific Sessions of the American Diabetes Association (ADA 2026)

Once-daily treatment with the highest orforglipron dose is associated with significant reductions in body weight and waist circumference at week 72 in women with obesity or overweight, regardless of menopausal status, according to a post hoc analysis of the phase III ATTAIN-1 and -2 trials presented at ADA 2026.

Treatment with a once-weekly injectable petrelintide, a novel human amylin analogue, yields up to 10.7 percent weight loss through week 42 in adults with obesity or overweight, according to the phase II ZUPREME-1 trial presented at ADA 2026.

In the phase II VESPER-2 trial, the investigational injectable glucagon-like peptide-1 receptor agonist (GLP-1 RA) berobenatide shows robust reductions in weight and HbA1c in adults with obesity/overweight and type 2 diabetes (T2D).

A recent study comparing dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, with orforglipron, an oral nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist (RA), has found superior glycaemic control and weight loss with the latter.

In a post hoc analysis of the phase III MAESTRO-NASH trial presented at ADA 2026, systemic thyroid function remained stable with resmetirom, supporting its extrahepatic safety in individuals with metabolic dysfunction-associated steatohepatitis (MASH).

For individuals with type 2 diabetes (T2D) that is inadequately controlled by diet and exercise alone, once-weekly administration of the triple hormone receptor agonist retatrutide helps improve glycaemic control, and this benefit is accompanied by substantial weight reduction, as shown in the phase III TRANSCEND-T2D-1 study.

Daily treatment with oral orforglipron, when added to titrated insulin glargine, has been shown to be beneficial in individuals with inadequately controlled type 2 diabetes (T2D) in the phase 3 ACHIEVE-5 trial.